+

WO1990009092A2 - Nouveaux inducteurs puissants de differenciation terminale et procede d'utilisation de tels inducteurs - Google Patents

Nouveaux inducteurs puissants de differenciation terminale et procede d'utilisation de tels inducteurs Download PDF

Info

Publication number
WO1990009092A2
WO1990009092A2 PCT/US1989/005203 US8905203W WO9009092A2 WO 1990009092 A2 WO1990009092 A2 WO 1990009092A2 US 8905203 W US8905203 W US 8905203W WO 9009092 A2 WO9009092 A2 WO 9009092A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
same
different
amount
Prior art date
Application number
PCT/US1989/005203
Other languages
English (en)
Other versions
WO1990009092A3 (fr
Inventor
Paul A. Marks
Richard A. Rifkind
Ronald Breslow
Original Assignee
The Trustees Of Columbia University In The City Of New York
Sloan-Kettering Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/374,343 external-priority patent/US5055608A/en
Application filed by The Trustees Of Columbia University In The City Of New York, Sloan-Kettering Institute For Cancer Research filed Critical The Trustees Of Columbia University In The City Of New York
Priority to PCT/US1990/002690 priority Critical patent/WO1991000257A1/fr
Priority to US07/522,558 priority patent/US5175191A/en
Priority to AU59271/90A priority patent/AU5927190A/en
Publication of WO1990009092A2 publication Critical patent/WO1990009092A2/fr
Publication of WO1990009092A3 publication Critical patent/WO1990009092A3/fr
Priority to JP03501924A priority patent/JP3083842B2/ja
Priority to CA002068224A priority patent/CA2068224C/fr
Priority to AU69726/91A priority patent/AU643248B2/en
Priority to PCT/US1990/006649 priority patent/WO1991008191A1/fr
Priority to AT91901442T priority patent/ATE175185T1/de
Priority to ES91901442T priority patent/ES2128314T3/es
Priority to EP91901442A priority patent/EP0594577B1/fr
Priority to DE69032871T priority patent/DE69032871T2/de
Priority to US08/424,556 priority patent/US5608108A/en
Priority to US08/476,624 priority patent/US5840960A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
    • C07D231/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Definitions

  • Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation.
  • chemotherapeutic treatment of cancer a) blocking hormone-dependent tumor cell proliferation by interference with the production or peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations.
  • cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (1).
  • differentiation has been reported by exposure of cells to a variety of stimuli, including: cyclic AMP and retinoic acid (2,3), aclarubicin and other anthracyclines (4).
  • neoplastic transformation does not necessarily destroy the potential of cancer cells to differentiate (1,5,6).
  • tumor cells which do not respond to the normal regulators of proliferation and appear to be blocked in the expression of their differentiation program, and yet can be induced to differentiate and cease replicating.
  • agents including some relatively simple polar compounds (5,7-9), derivatives of vitamin D and retinoic acid (10-12), steroid hormones (13), growth factors (6,14), proteases (15,16), tumor promoters (17,18), and inhibitors of DNA or RNA synthesis (4,19-24), can induce various transformed cell lines and primary human tumor explants to express more differentiated characteristics.
  • HMBA hybrid polar/apolar compound N,N'-hexamethylene bisacetamide
  • MELC terminal erythroid differentiation is a multistep process.
  • HMBA HMBA to MELC (745A-DS19) in culture
  • Commitment is defined as the capacity of cells to express terminal differentiation despite removal of inducer (25).
  • HMBA Upon continued exposure to HMBA there is progressive recruitment of cells to differentiate.
  • MELC cell lines made resistant to relatively low levels of vincristine become markedly more sensitive to the inducing action of HMBA and can be induced to differentiate with little or no latent period (26).
  • HMBA is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cells lines (5).
  • the characteristics of the drug induced effect have been most extensively studied in the murine erythroleukemia cell system (MELC) (5,25,27,28).
  • MELC induction of differentiation is both time and concentration dependent.
  • the minimum concentration required to demonstrate an effect in vitro in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in a substantial portion (>20%) of the population without continuing drug exposure is about 36 hours.
  • HMBA have been completed (31-36). Recently, the first evidence was reported that this compound can induce a therapeutic response in patients with cancer (35,36). These phase I clinical trials demonstrate that the potential efficacy of HMBA is limited, in part, by dose-related toxicity which prevents achieving optimal blood levels and by the need for intravenous administration of large quantities of the agent, over prolonged periods.
  • the present invention provides new chemical inducers which are 2-20 times more active than HMBA. It has unexpectedly been found that compounds having two or more nonpolar components connected by a polar group and having groups on the termini of the compound are effective inducers of terminal differentiation. For instance, bis-hexamethylene triacetamide, which comprises three acetamide groups connected by two six-carbon chains, has been found to be a potent inducer of terminal differentiation in MELC.
  • This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.
  • the invention provides a class of compounds having the structure:
  • each of A, A 1 , A 2 , A 3 , and A 4 represent a polar group which comprises a nitrogen, sulfur or oxygen atom wherein each of A, A 1 , A 2 , A 3 , and A 4 may independently be the same as, or different from, the others of A, A 1 , A 2 , A 3 , and A 4 ; wherein each of R and R 1 is a hydrogen atom; a lower alkyl, alkenyl, or alkynyl group; or a group having the structure:
  • each of R 2 and R 3 being a hydrogen atom or a lower alkyl, alkenyl, or alkynyl group; and wherein each of R, R 1 , R 2 and R 3 may independently be the same as, or different from the other of R, R 1 , R 2 and R 3 ; wherein each of [R-A] and [A 4 -R 1 ] have a dipole moment greater than about 2.7 Debye units; wherein each of B, B 1 , B 2 , and B 3 represents a nonpolar group which comprises at least 4 atoms in a chain, the termini of which chains are attached to A and A 1 , A 1 and A 2 , A 2 and A 3 , and A 3 and A 4 , respectively; wherein each such atom is oxygen, nitrogen, carbon, or sulfur and wherein each of B, B 1 , B 2 , and B 3 ; and wherein each of a and b is independently 0 or 1.
  • the invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effective to selectively induce terminal differentiation.
  • the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation, and suppressing oncogenicity.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound in an amount less than an amount which cause toxicity in the patient.
  • Figure 1 Comparison of the hybrid polar/apolar compounds, (A) hexamethylene bisacetamide (HMBA); (B) suberic acid bis-N-methyl diacetamide (SBDA); and (C) bis- hexamethylene triacetamide (BHTA) as inducers of differentiation of vincristine-sensitive (745A-DS19) ( ⁇ ) and vincristine-resistant (VCR.C(2) 15) ( ⁇ )
  • HMBA hexamethylene bisacetamide
  • SBDA suberic acid bis-N-methyl diacetamide
  • BHTA bis- hexamethylene triacetamide
  • Figure 2 Concentration dependent curves of inducer activity of compound 12 with vincristine- sensitive (745A-DS19) ( ⁇ ) and vincristine- resistant (VCR.C(2)15) ( ⁇ ) MELC. The compound was added to the cultures at the final concentrations indicated. Benzidine reactive cells were determined after 5 d. in culture and commitment after 2 d. of culture.
  • Figure 3 optimal concentration of IC-135 for inducement of terminal differentiation.
  • Figure 4 Comparison of HMBA and IC-135 on DS19 cells.
  • the invention provides a class of compounds having the structure:
  • each A, A 1 , A 2 , A 3 , and A 4 represent a polar group which comprises a nitrogen, sulfur or oxygen atom and wherein each of A, A 1 , A 2 , A 3 , and A 4 may independently be the same as, or different from, the others of A, A 1 , A 2 , A 3 , and A 4 ; wherein each of R and R 1 is a hydrogen atom; a lower alkyl, alkenyl, or alkynyl group; or a group having the structure:
  • each of R 2 and R 3 being a hydrogen atom or a lower alkyl, alkenyl, or alkynyl group; and wherein each of R, R 1 , R 2 an
  • R 3 may independently be the same as, or different from, th others of R, R 1 , R 2 and R 3 ; wherein each of [R-A] and [A 4 -R 1 ] have a dipolar momen greater than about 2.7 Debye units; wherein each of B, B 1 , B 2 , and B 3 represents a nonpolar group which comprises at least 4 atoms in a chain, th termini of which chains are attached to A and A 1 , A 1 and A 2 , A 2 and A 3 , and A 3 and A 4 , respectively; wherein each suc atom is oxygen, nitrogen, carbon, or sulfur and wherein each of B, B 1 , B 2 , and B 3 ; and wherein each of a and b is independently 0 or 1.
  • the compounds of the present invention are made up of two components.
  • One component comprises a polar group, i.e. functional groups with significant dipole moments, such as amides, sulfoxides, amine oxides and related functional groups.
  • the terminal portions of the compound each have dipole moments greater than about 2.7 debye units.
  • the polar groups within the compound represented by -A 1 , -A 2 - and -A 3 -, have significant dipolar moments but not necessarily in excess of 2.7 debye units.
  • the polar groups are carbonyl radicals or bivalent radicals of an amide, a sulfoxide or a amine oxide.
  • Each polar group need not necessarily be the same as the other polar groups.
  • the poplar groups within the compound are the same as each other and the terminal polar groups are the same.
  • all the polar groups are amide groups attached to the compound at the nitrogen atom or at the carbon atom of the carbonyl radical.
  • the amide group may comprise one or more hydrocarbon substituents, such as a lower alkyl or alkenyl groups, including branched or unbranched groups.
  • the term "lower alkyl or alkenyl group” is intended to include saturated and unsaturated hydrocarbon groups with 1 to about 5 carbon atoms.
  • R 4 is a hydrogen atom or a lower alkyl or alkenyl group
  • A is a carbonyl radical and R has the structure:
  • R 2 and R 3 each is hydrogen atom, a methyl group or a ethyl group.
  • the compound also requires at least two nonpolar sections, designated B and B 1 , which are attached to and connect polar groups. Additional nonpolar sections may also be present, e.g. B 2 when a is 1 and B 3 when b is 1.
  • the nonpolar sections may comprise linear saturated hydrocarbon chains, linear unsaturated hydrocarbon chains containing one or more double or triple bonds, or saturated or unsaturated hydrocarbon chains containing one or more lower alkyl or alkenyl groups or small carbocyclic rings as substituents.
  • the nonpolar groups are hydrocarbon chains comprising 4 to 7 methylene groups, especially preferred are hydrocarbon chains containing 6 carbon atoms.
  • the preferred compounds for the practice of the present invention are those having the structures:
  • R is hydrogen or a methyl group and x is 5 or 6.
  • R1 and R2 may be the same or different and each is a lower alkyl group
  • R is H or a lower alkyl group
  • n is an integer which is greater than 3 and R 1 and R 2 may be the same or different and each is H or a lower alkyl group; a compound having the structure:
  • X1 and X2 may be the same or different and each is N(CH3)2 or HNCH 3 ;
  • R1 and R2 may be the same or different and is H or CH3; a compound having the structure:
  • R1 and R2 may be the same or different and each is H or CH3; a compound having the structure:
  • R1 and R2 may be the same or different and is H or a lower alkyl group; a compound having the structure:
  • R1 and R2 may be the smae or different and is H or a lower alkyl group.
  • the invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compounds shown above effective to selectively induce terminal differentiation in the cells.
  • the contacting must be performed continuously for prolonged period of time, i.e. for at least 48 hours, preferably for abut 4-5 days or longer.
  • the method may be practiced in vivo or in vitro. If the method is practiced in vitro, contacting may be effectiv by incubating the cells with the compound.
  • the concentration of the compound in contact with the cells should be from about 0.5 to 25 mM, preferably from about 1 mM to about 5 mM. However, for most preferred compound having the structure: 8 spaces, an amount of about 0.01 mM to about 10 mM has been shown to be effective.
  • the concentration depends upon the individual compound.
  • compound 12 of Table 1 should have a concentration from about 0.1 to about 2 mM, preferably from about 0.5 to However, for the most preferred compound having the structure:
  • the concentration depends upon the individual compound.
  • compound 12 of Table 1 should have a concentration from about 0.1 to about 2 mM, preferably from about 0.5 to about 0.7 mM.
  • Another factor determining the preferable range is the state of the tumor cells.
  • the range of effective concentration of compound 12 from Table 1 is from about 0.01 to about 0.3 mM with a preferable range of about 0.05 to about 0.1 mM.
  • the invention also concerns a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compounds shown above effective to selectively induce terminal differentiation of such neoplastic cells thereby inhibiting their proliferation, and suppressing oncogenicity.
  • the method of the present invention is intended for the treatment of human patients with tumors. However, it is also likely that the method would be effective in the treatment of tumors in other animals.
  • the term tumor is intended to include any cancer caused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carcinoma, breast carcinoma, or colorectal carcinoma.
  • the administration of the compound to the patient may be effected orally or parenterally. To date, administration intravenously has proven to be effective.
  • the administration of the compound must be performed continuously for a prolonged period of time, such as for at least 3 days preferably more than 5 days.
  • the administration is effected continuously for at least 10 days and is repeated at intervals wherein at each interval the administration is continuously effected for at least 10 days.
  • the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval.
  • the optimal interval period will vary depending on the type of patient and tumor. For example, in the incidence of acute leukemia, the so called myelodysplastic syndrome, continuous infusion would seem to be indicated so long as the patient tolerated the drug without toxicity and there was a positive response.
  • the amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient.
  • the compound has the structure:
  • the amount of the compound which is administered to the patient is less than the amount which causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound.
  • the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found with HMBA that administration of the compound in an amount from about 5 gm/m 2 /day to about 30 gm/m 2 /day, particularly about 20 gm/m 2 /day, is effective without producing toxicity in the patient.
  • the optimal amount of the compounds is substantially lower than 30 gm/m 2 /day, and may even be lower than 1 gm/m 2 /day.
  • the optimal amount of the compound which should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.
  • homologs are molecules having substantial structural similarities to the above- described compounds and analogs are molecules having substantial biological similarities regardless of structural similarities.
  • the invention also concerns a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier, such as sterile pyrogen-free water, and the compound in an amount less than an amount which if administered intravenously or orally to a patient would cause the patient's blood plasma concentration of the compound to exceed toxic levels.
  • a pharmaceutically acceptable carrier such as sterile pyrogen-free water
  • MELC 745A-DS19 cells and the variants of MELC derived from this cell line namely, the vincristine-resistant MELC V3.17 and VCR.C(2)15 cell lines (26), and the dimethylsulfoxide-resistant cell line, DR10 (37), were maintained in alpha minimal essential medium containing 10% fetal calf serum (16).
  • Cell cultures for all experiments were initiated with cells in logarithmic growth phase (day 2 cultured cells) at a density of 10 cells/ml. Inducer compounds were added in the final concentrations indicated below, dissolved in culture medium without fetal calf serum unless otherwise indicated. Cell density and benzidine reactively were determined as described (16).
  • Compound 12 (Table 1) was prepared by simple dialkylation of dimethyl malonate with the know N,N'-dimethyl-6-bromohexanecarboxamide (39).
  • Each compound in Table 1 was assayed 3 or more times to determine effectiveness as an inducer of MELC (745A-DS19) cell line.
  • the cell density of MELC in culture for 5 d. without inducer was 2.0 to 2.6 ⁇ 10 6 cells/ml.
  • the cell density of MELC in culture for 5 d. with inducer was 1.2 to 2.0 ⁇ 10 6 cells/ml.
  • Compounds 11 and 12 were dissolved in absolute ethyl alcohol.
  • the final concentration of ethyl alcohol in the cultured medium ranged between 0.1 and 3%. This concentration of ethyl alcohol had no effect on cell growth of MELC in culture without inducer. All other compounds were dissolved in culture medium without fetal calf serum. The indicated optimal concentration represents the final concentration in the culture medium.
  • HMBA hexamethylene bisacetamide
  • Acetamide can also be dimerized by linking the methyl groups of the molecule.
  • Suberic acid bis-N-methylamide (SBDA; Table 1, compound 7), can be thought of as N-methylacetamide linked at the acetyl group by four methylene units.
  • SBDA is comparable in activity as an inducer to HMBA ( Figure 1A and B). Since the structures of SBDA and HMBA are different, it is likely that the metabolic fates of these two compounds are completely different, and their similarity in effectiveness means that the compounds themselves are the principal active agents, rather than their catabolic products.
  • HMBA and SBDA have their polar groups separated by identical methylene bridges, and they have a similar ratio of polar to apolar hydrophobic moieties.
  • This compound with 4 exposed polar groups balanced by two apolar pentamethylene domains, is roughly 10 fold more active than HMBA.
  • 0.6 mM compound 12 is about as effective as 5.0 mM HMBA, inducing over 90% of cells to differentiate after 5 d. in culture (Fig. 2).
  • HMBA Polymethylenediamine derivatives carrying propionyl groups instead of the acetyl groups of HMBA are also active, but methoxycarbonyl groups are less effective and bulky pivaloyl groups lead to loss of activity.
  • the present inventors previously showed that HMBA can have a double bond (cis or trans) or a triple bond in the center and retain its activity (27). Replacement of the polymethylene chain with a cyclohexane ring leads to inactivity (27), although compound 9., with a longer chain interrupted by an amide group, is active.
  • Diamides of dicarboxylic acids such as suberic acid, are active with either one or two methyl groups on each nitrogen (compounds 7, 8 , and 9), but not with a methyl and a methoxyl substituent, and they are also active with one (but not two) ethyl groups on each nitrogen.
  • Suberic diamides of pyrollidine, of morpholine, or of piperazine are inactive. This shows that there is a limit to the amount of carbon tolerated on the ends of the polar groups.
  • vincristine-resistant MELC were induced at lower concentrations than were required for induction of vincristine-resistant MELC were induced more rapidly than the vincristine-sensitive cells.
  • 0.1 mM compound 12 was the optimal concentration for inducing vincristine-resistant MELC (VCR. C(2) 15).
  • VCR. C(2) 15 the optimal concentration for inducing vincristine-resistant MELC
  • 0.1 mM compound 12 induced only 6% commitment of over 95% of V.C.R. (2) 15 cells after 2 d. and the accumulation of over 80% benzidine-sensitive (DS-19) MELC
  • 0.1 mM compound 12 induced only 6% commitment by d. 2 and 4% benzidine reactive cells by d. 5.
  • HMBA Hexamethylenebisacetamide
  • Table 2 shows the cell densities, B+%, and percent of cells committed for cell lines DS19 and V3.17 grown in 1 mM to 5 mM of HMBA and IC-135.
  • Figures 3, 4, 5A and B, and 6A and B are graphical representations of the data presented in Table 2.
  • Table 3 shows cell counts for days 1, 2 and 5 and percentage of cells committed and benzidine reactive (B+) at day 5 for cell liens DS-19, V3.17 and DR-10 grown in 5 mM of HMBA and 0.5 to 3 mM of IC-135. As can be seen in Table 2 and 3 and Figures 3-6, IC-135 is more reactive in the tested cell lines at lower concentrations than HMBA.
  • agents which can induce transformed cells to differentiate and suppress their oncogenicity has important implications for the treatment of cancer. While a number of agents have been identified that can induce tumor cells in vitro to express features of their differentiated phenotype and to decrease their proliferative capacity (4,10-24), these agents have generally proved to be relatively ineffective or two toxic when evaluated in clinical trials (40).
  • the hybrid polar/apolar compound, HMBA has been one of the best characterized with respect to its in vitro inducing activity in MELC and in a number of other transformed cell lines, as well as for certain human tumor explants (30). It can trigger a differentiation program in transformed cells which is similar to that of their normal lineage (5).
  • the observed positive therapeutic responses to HMBA albeit largely transient, occurred despite relatively low serum concentrations of HMBA ( ⁇ 1 mM), compared to the optimum demonstrated in vitro (4 to 5 mM) (35,36).
  • the present invention provides a new group of hybrid polar/apolar compounds which are as active or even more active, on a molar basis, than HMBA.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention se rapporte à une classe de composés ayant au moins deux composants non polaires reliés par un groupe polaire et comportant des groupes polaires sur les terminaisons du composé. La présente invention se rapporte également à un procédé permettant d'induire sélectivement la différenciation des terminaisons des cellules néoplastiques et, par conséquent, d'inhiber la prolifération de telles cellules. Ledit procédé consiste à mettre en contact les cellules dans des conditions appropriées avec une quantité du composé suffisante pour induire sélectivement la différenciation terminale. La présente invention se rapporte en outre à un procédé permettant de traiter un patient ayant une tumeur qui se caractérise par la prolifération de cellules néoplastiques. Ledit procédé consiste à administrer au patient une quantité du composé suffisante pour induire sélectivement la différenciation terminale de ces cellules néoplastiques afin d'inhiber leur prolifération et de supprimer l'oncogénicité. La présente invention se rapporte enfin à une préparation pharmaceutique contenant un excipient pharmaceutiquement acceptable et le composé en une quantité efficace inférieure à une quantité qui entraînerait une toxicité pour le patient.
PCT/US1989/005203 1988-11-14 1989-11-14 Nouveaux inducteurs puissants de differenciation terminale et procede d'utilisation de tels inducteurs WO1990009092A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PCT/US1990/002690 WO1991000257A1 (fr) 1989-06-30 1990-05-14 Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
US07/522,558 US5175191A (en) 1988-11-14 1990-05-14 Potent inducers of terminal differentiation and methods of use thereof
AU59271/90A AU5927190A (en) 1989-06-30 1990-05-14 Novel potent inducers of terminal differentiation and methods of use thereof
DE69032871T DE69032871T2 (de) 1989-11-14 1990-11-14 Neue potente induktoren terminaler differenzierung und verfahren zu ihrer verwendung
EP91901442A EP0594577B1 (fr) 1989-11-14 1990-11-14 Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
ES91901442T ES2128314T3 (es) 1989-11-14 1990-11-14 Nuevos inductores potentes de diferenciacion terminal y metodo de utilizacion de los mismos.
CA002068224A CA2068224C (fr) 1989-11-14 1990-11-14 Nouveaux inducteurs efficaces de la phase terminale de la differenciation et methode d'utilisation
JP03501924A JP3083842B2 (ja) 1989-11-14 1990-11-14 新規かつ強力な最終分化誘発剤及びその使用方法
AU69726/91A AU643248B2 (en) 1989-11-14 1990-11-14 Novel potent inducers of terminal differentiation and method of use thereof
PCT/US1990/006649 WO1991008191A1 (fr) 1989-11-14 1990-11-14 Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
AT91901442T ATE175185T1 (de) 1989-11-14 1990-11-14 Neue potente induktoren terminaler differenzierung und verfahren zu ihrer verwendung
US08/424,556 US5608108A (en) 1988-11-14 1995-04-17 Potent inducers of terminal differentiation and method of use thereof
US08/476,624 US5840960A (en) 1988-11-14 1995-06-07 Potent inducers of terminal differentiation and method of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27096388A 1988-11-14 1988-11-14
US270,963 1988-11-14
US07/374,343 US5055608A (en) 1988-11-14 1989-06-30 Novel potent inducers of thermal differentiation and method of use thereof
US374,343 1989-06-30

Publications (2)

Publication Number Publication Date
WO1990009092A2 true WO1990009092A2 (fr) 1990-08-23
WO1990009092A3 WO1990009092A3 (fr) 1990-10-04

Family

ID=26954600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/005203 WO1990009092A2 (fr) 1988-11-14 1989-11-14 Nouveaux inducteurs puissants de differenciation terminale et procede d'utilisation de tels inducteurs

Country Status (4)

Country Link
JP (1) JPH04500359A (fr)
AU (1) AU4835090A (fr)
CA (1) CA2002853A1 (fr)
WO (1) WO1990009092A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594577A1 (fr) * 1989-11-14 1994-05-04 Sloan-Kettering Institute For Cancer Research Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
US7879865B2 (en) 2001-10-16 2011-02-01 Sloan-Kettering Institute For Cancer Research Treatment of cancer of the brain using histone deacetylase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1123574B (it) * 1979-09-10 1986-04-30 Anic Spa Processo per la produzione di diesterediammidi
US4882346A (en) * 1987-06-16 1989-11-21 The United States Of America As Reprsented By The Department Of Health And Human Services Chemical differentiating agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594577A1 (fr) * 1989-11-14 1994-05-04 Sloan-Kettering Institute For Cancer Research Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
EP0594577A4 (en) * 1989-11-14 1994-05-18 Sloan Kettering Inst Cancer Novel potent inducers of terminal differentiation and method of use thereof
US7879865B2 (en) 2001-10-16 2011-02-01 Sloan-Kettering Institute For Cancer Research Treatment of cancer of the brain using histone deacetylase inhibitors

Also Published As

Publication number Publication date
WO1990009092A3 (fr) 1990-10-04
AU4835090A (en) 1990-09-05
JPH04500359A (ja) 1992-01-23
CA2002853A1 (fr) 1990-05-14

Similar Documents

Publication Publication Date Title
US5055608A (en) Novel potent inducers of thermal differentiation and method of use thereof
US5840960A (en) Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) Potent inducers of terminal differentiation and methods of use thereof
US6087367A (en) Potent inducers of terminal differentiation and methods of use thereof
EP0760657B9 (fr) Nouveaux inducteurs puissants de la differenciation terminale et leurs procedes d'utilisation
Marks et al. Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential.
USRE38506E1 (en) Potent inducers of terminal differentiation and methods of use thereof
CN102149673B (zh) 脂肪酸乙酰化的水杨酸酯及其用途
US6511990B1 (en) Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
AU643248B2 (en) Novel potent inducers of terminal differentiation and method of use thereof
WO1991000257A1 (fr) Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
WO1990009092A2 (fr) Nouveaux inducteurs puissants de differenciation terminale et procede d'utilisation de tels inducteurs
AU708115B2 (en) Novel potent inducers of terminal differentiation and methods of use thereof
JPWO2002043760A1 (ja) 糖代謝活性化剤
RU2800042C1 (ru) Спиросоединения в качестве ингибиторов ERK и их применение
CA2574103A1 (fr) Nouveaux inducteurs puissants de la differenciation terminale et leurs procedes d'utilisation
US4033974A (en) Pyridylmethyl esters of N-(phenoxyalkanoyl)peptide derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI HU JP KP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI HU JP KP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载